TAS2R5 Antibody, HRP conjugated

Target Biology and Epitope

TAS2R5 is a G protein-coupled receptor (GPCR) involved in bitter taste perception and extraoral signaling. The antibody targets a peptide epitope within residues 178–227 of the human TAS2R5 protein, ensuring specificity . Its molecular weight is approximately 34.5 kDa, as confirmed by western blot .

3.1. ELISA and Protein Quantification

The HRP-conjugated TAS2R5 antibody has been utilized in Alzheimer’s disease (AD) research to quantify protein levels in the orbitofrontal cortex (OFC). Key findings include :

• Progressive reduction in TAS2R5 protein levels starting at Braak stage II (early AD) through Braak V (advanced AD).

• Correlation with mRNA downregulation, suggesting epigenetic silencing precedes protein loss.

• Cellular localization: Expressed in neurons, astrocytes, and brain microvascular endothelial cells .

3.2. Western Blot (WB)

While primarily validated for ELISA, polyclonal TAS2R5 antibodies (non-conjugated) show reactivity in WB at dilutions of 1:500–1:2000 . HRP conjugation enhances sensitivity for low-abundance targets.

4.1. Role in Neurodegenerative Disease

• Epigenetic regulation: H3K9me3 histone modifications and MeCP2 interactions at TAS2R5 promoters correlate with transcriptional repression in early AD .

  • Braak I: Significant H3K9me3 enrichment at coding regions ($P = 0.0172$) .

  • Braak IV/V: Loss of H3K9me3 marks ($P < 0.0001$), associated with disease progression .

• Protein levels: Reduced by >50% in advanced AD stages compared to non-demented controls .

4.2. Cancer Research Insights

Though not directly studied, TAS2R14 (a related bitter receptor) shows prognostic significance in papillary thyroid carcinoma (PTC):

• Higher TAS2R14 expression correlates with improved progression-free survival ($P = 0.01$) .

• TAS2R agonists induce apoptosis in PTC cells, suggesting therapeutic potential for TAS2R-targeted therapies .

Validation and Quality Control

• Specificity: Verified via peptide-blocking assays and cross-reactivity tests .

• Reproducibility: Batch-to-batch consistency confirmed by stain-free total protein normalization in WB .

• Storage: Stable at -20°C long-term; avoid freeze-thaw cycles .

Comparative Analysis of TAS2R5 Antibodies

Limitations and Future Directions

• Sensitivity: HRP conjugation limits multiplexing compared to fluorophore-labeled alternatives.

• Tissue specificity: Limited data outside neuronal and endocrine tissues.

• Therapeutic potential: Mechanistic studies linking TAS2R5 signaling to disease pathways remain sparse.